Advanced

Analysis of Alpha-Synuclein in Malignant Melanoma - Development of a SRM Quantification Assay.

Welinder, Charlotte LU ; Jönsson, Göran B LU ; Ingvar, Christian LU ; Lundgren, Lotta LU ; Baldetorp, Bo LU ; Olsson, Håkan LU ; Breslin, Thomas LU ; Rezeli, Melinda; Jansson, Bo LU and Fehniger, Thomas E, et al. (2014) In PLoS ONE 9(10).
Abstract
Globally, malignant melanoma shows a steady increase in the incidence among cancer diseases. Malignant melanoma represents a cancer type where currently no biomarker or diagnostics is available to identify disease stage, progression of disease or personalized medicine treatment. The aim of this study was to assess the tissue expression of alpha-synuclein, a protein implicated in several disease processes, in metastatic tissues from malignant melanoma patients. A targeted Selected Reaction Monitoring (SRM) assay was developed and utilized together with stable isotope labeling for the relative quantification of two target peptides of alpha-synuclein. Analysis of alpha-synuclein protein was then performed in ten metastatic tissue samples from... (More)
Globally, malignant melanoma shows a steady increase in the incidence among cancer diseases. Malignant melanoma represents a cancer type where currently no biomarker or diagnostics is available to identify disease stage, progression of disease or personalized medicine treatment. The aim of this study was to assess the tissue expression of alpha-synuclein, a protein implicated in several disease processes, in metastatic tissues from malignant melanoma patients. A targeted Selected Reaction Monitoring (SRM) assay was developed and utilized together with stable isotope labeling for the relative quantification of two target peptides of alpha-synuclein. Analysis of alpha-synuclein protein was then performed in ten metastatic tissue samples from the Lund Melanoma Biobank. The calibration curve using peak area ratio (heavy/light) versus concentration ratios showed linear regression over three orders of magnitude, for both of the selected target peptide sequences. In support of the measurements of specific protein expression levels, we also observed significant correlation between the protein and mRNA levels of alpha-synuclein in these tissues. Investigating levels of tissue alpha-synuclein may add novel aspect to biomarker development in melanoma, help to understand disease mechanisms and ultimately contribute to discriminate melanoma patients with different prognosis. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
PLoS ONE
volume
9
issue
10
publisher
Public Library of Science
external identifiers
  • pmid:25333933
  • wos:000343731200076
  • scopus:84908191937
ISSN
1932-6203
DOI
10.1371/journal.pone.0110804
language
English
LU publication?
yes
id
d3678885-848e-4677-a689-6c1c5440a75c (old id 4733646)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25333933?dopt=Abstract
date added to LUP
2014-11-10 17:17:32
date last changed
2017-06-11 04:04:02
@article{d3678885-848e-4677-a689-6c1c5440a75c,
  abstract     = {Globally, malignant melanoma shows a steady increase in the incidence among cancer diseases. Malignant melanoma represents a cancer type where currently no biomarker or diagnostics is available to identify disease stage, progression of disease or personalized medicine treatment. The aim of this study was to assess the tissue expression of alpha-synuclein, a protein implicated in several disease processes, in metastatic tissues from malignant melanoma patients. A targeted Selected Reaction Monitoring (SRM) assay was developed and utilized together with stable isotope labeling for the relative quantification of two target peptides of alpha-synuclein. Analysis of alpha-synuclein protein was then performed in ten metastatic tissue samples from the Lund Melanoma Biobank. The calibration curve using peak area ratio (heavy/light) versus concentration ratios showed linear regression over three orders of magnitude, for both of the selected target peptide sequences. In support of the measurements of specific protein expression levels, we also observed significant correlation between the protein and mRNA levels of alpha-synuclein in these tissues. Investigating levels of tissue alpha-synuclein may add novel aspect to biomarker development in melanoma, help to understand disease mechanisms and ultimately contribute to discriminate melanoma patients with different prognosis.},
  articleno    = {e110804},
  author       = {Welinder, Charlotte and Jönsson, Göran B and Ingvar, Christian and Lundgren, Lotta and Baldetorp, Bo and Olsson, Håkan and Breslin, Thomas and Rezeli, Melinda and Jansson, Bo and Fehniger, Thomas E and Laurell, Thomas and Wieslander, Elisabet and Pawlowski, Krzysztof and Marko-Varga, György},
  issn         = {1932-6203},
  language     = {eng},
  number       = {10},
  publisher    = {Public Library of Science},
  series       = {PLoS ONE},
  title        = {Analysis of Alpha-Synuclein in Malignant Melanoma - Development of a SRM Quantification Assay.},
  url          = {http://dx.doi.org/10.1371/journal.pone.0110804},
  volume       = {9},
  year         = {2014},
}